GSK plc · LSE:GSK
GSK — Economist Pharma Summit: Reinventing Pharma for a New Generation (February 2011)
16 slides from GSK's conference presentation, Feb 10, 2011
Slide 1: Pharma's value proposition — how the industry must change
ft 4 y, e sk Pharma’s value proposition — how the industry must change David Redfern Chief Strategy Officer, GSK 10 February 2011 Economist Pharma Summit: Reinventing Pharma for a New Generation
Slide 2: Slide 2
Slide 3: GSK's strategic priorities
GSK’s strategic priorities = Grow a diversified global business = Deliver more products of value = Simplify the operating model
Slide 4: More medicines to those who need them
More medicines to those who need them Improve access Cancers to GSK Heart disease medicines COPD Diabetes Asthma Diarrhoeal Disease Malaria
Slide 5: Geographic spread of GSK's Emerging Markets business
Geographic spread of GSK’s Emerging Markets business ~13,000 sales reps 85 co untries Peas as ~— os Emerging Markets FY10 £3.6bn (+22%) = 13% of GSK Group Turnover Source: GSK FY 10 reported turnover
Slide 6: GSK - a truly global company
GSK - a truly global company Consumer Healthcare: 18% of GSK Respiratory: 27% of GSK +5% in 2010 +3% in 2010 Source: GSK FY 2010 turnover
Slide 7: Market access and flexible pricing initiatives across Emerging Markets
Market access and flexible pricing initiatives across Emerging Markets Avodartin Russia: Optimal pricing delivers rapid uptake Avodart unit growth, BPH market =~ # packs #packs # patients Tykerb in India: Optimal pricing delivers rapid uptake and fewer discontinuations —*— Total Volume (left axis) —
Slide 8: Votrient in the UK
Votrient in the UK = Currently only one treatment for RCC recommended by NICE = Votrient to be available at a discount of 12.5% = Means it will be accessible to patients quickly = Also offered a potential future financial rebate dependent on the outcome of a H2H trial vs current standard of care = I
Slide 9: Pipeline maturing while maintaining ~30 assets in late-stage development
Pipeline maturing while maintaining ~30 assets in _iateotage development | ~ Late stage examples RTS.S Darapladib MAGE-3 Benlysta (Malaria vaccine) (Atherosclerosis) (Melanoma vaccine) (SLE) Albiglutide Otelixumab Relovair (Type 2 Diabetes) (Type 1 Diabetes) (Asthma/ COPD) Nine assets moved into lat
Slide 10: Creating a broader portfolio of potential high value assets as generic exposure declines
Creating a broader portfolio of potential high value assets as generic exposure declines New products contributions in 2010 * £1.73bn+36% « Pandemic vaccine also added £1.2bn (% prolia _Jalyn) Goals /seesansa Arzerra() wese® § Arzerrar'() CERT ofatumumab GER ofatumumab Hiberix |, t(\ Hiberix,, © t(\
Slide 11: Discovery Performance Units
Discovery Performance Units Respiratory Metabolic Pathways Immuno-inflammation Infectious Diseases » Fibrosis > Heart Failure > EpiNova » HCV » Neuronal Targets > Lipid Metabolism > Tempero > HIV » Therapeutic >» Enteroendocrine } Mechanistic Med » Antibacterial SIRNA ; > Muscle > Pattern » Allergic
Slide 12: Driving shareholder returns
Driving shareholder returns shareholder return
Slide 13: Responsible business
Responsible business PULSE THE GSK VOLUNTEER PARTNERSHIP 2, ererge 13
Slide 14: Least Developed Countries
Least Developed Countries : _ Price cap of 25% of westem prices Wonld’s 50 poorest countries (UN definition) (patented medicines) Reinvest 20% of profits from medicines in 50% survive on less than US$1 per day LDCs back into healthcare infrastructure : Active partnership: albendazole, malaria Weak h
Slide 15: Slide 15
Slide 16: GlaxoSmithKline
GlaxoSmithKline
GSK — Economist Pharma Summit: Reinventing Pharma for a New Generation (February 2011) on 6ix